Savara Inc. (NASDAQ:SVRA) Q1 2020 Earnings Conference Call - Final Transcript

May 07, 2020 • 04:30 pm ET

Previous

Savara Inc. (NASDAQ:SVRA) Q1 2020 Earnings Conference Call - Final Transcript

Share
Close

Loading Event

Loading Transcript

Presentation
Operator
Operator

Good day and welcome to the Savara conference call. [Operator Instructions] An audio webcast of this call will be available on the Investors section of Savara's website at savarapharma.com. This call is subject to copyright and is the property of Savara. All recordings, reproduction, and transmission of this call without the expressed written consent of Savara is strictly prohibited. [Operator Instructions]

I would now like to turn the call over to Anne Erickson, Head Investor Relations and Corporate Communications at Savara. Please go ahead, ma'am.

Executive
Anne Erickson

Good afternoon, and thank you for joining us today. A press release reporting our first quarter 2020 financial results was issued earlier today, May 7, 2020, and can be found on the Investors section of our Web site, at savarapharma.com. If you've not received this release or you would like to be added to the company's distribution list, please e-mail me at ir@savarapharma.com.

This call is also being webcast live, and one hour after the call a replay will be available on the Company's Web site, and will remain available for the next 30 days. A telephone replay will be available through May 14. Today's conference call and webcast contain forward-looking statements within the meaning of federal securities laws, including statements regarding the company's strategy, goals, product candidates, clinical studies, and financing matters. Such statements are subject to significant risks and uncertainties, including those described in our press release issued today, Thursday, May 7, 2020, and our recent SEC filings on Forms 8-K, 10-K, and 10-Q.

Actual results or performance may differ materially from the expectations indicated by our forward-looking statements due to those risks and uncertainties. We caution you not to place undue reliance on any of the forward-looking statements, which speak only as of today. We will take analysts' questions at the end of the call; however we encourage shareholders to submit questions via e-mail to ir@savarapharma.com. Time permitting; we will address these questions alongside any others that we've received today.

Joining me on the call today are Rob Neville, Chief Executive Officer; Badrul Chowdhury, Chief Medical Officer; Dave Lowrance, Chief Financial Officer; and Taneli Jouhikainen, President and Chief Operating Officer.

I'll now turn the call over to Rob.

Executive
Rob Neville

Thank you, Anne, and thank you everybody for joining us on the call this afternoon, appreciate that. I wanted to start by saying that despite the widespread and far-reaching impact of COVID-19, we've enjoyed a strong start to the new year. This is a testament to the commitment and talent of my colleagues that has allowed us to navigate these unchartered waters with confidence and an eye on the future. While no one knows how long the uncertainty of the situation will last, Savara's Board and Management team alongside our employees remain focused on our mission, again to back up for COVID-19, our commitment to patients have never been more important, and that commitment is reflected in everything we do.

With regarding our programs, we've marked a continued discussion with the FDA about IMPALA 2.